Skip to main content

Table 2 Characteristics of pDILI Type 1 cases (BTS/ATS criteria) and controls

From: Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK

Characteristic   Controls DILI cases  
   Median (IQR) Median (IQR) P-value
Baseline ALT (IU/L)   19 (14–29), n = 185 24 (17–32), n = 77 0.03
Baseline ALP (IU/L)   86 (71–102), n = 187 98 (75–135), n = 77 0.03
Baseline bilirubin (umol/L) 8 (5–10), n = 185 8 (6–12), n = 77 0.28
Weight (kg)   61.2 (54.5–69.6), n = 178 53.9 (48.0–65.0), n = 74 0.001
Rifampicin dose per kg (if given) 9.68 (8.62–10.7), n = 178 9.98 (9.00–11.1), n = 74 0.17
Isoniazid dose per kg (if given) 4.85 (4.31–5.45), n = 178 5.57 (4.62–6.25), n = 74 <0.001
Pyrazinamide dose per kg (if given) 24.4 (21.4–27.5), n = 178 25.8 (22.7–29.8), n = 74 0.05
Moxifloxacin dose per kg (if given) 6.15 (5.71–7.04), n = 21 7.67 (5.71–8.00), n = 10 0.20
   % (fraction) % (fraction)  
HIV positive   2.2 (4/185) 7.3 (5/69) 0.06
HCV positive   1.7 (3/179) 1.4 (1/73) 1.00
HBV positive   2.2 (4/180) 0.0 (0/74) 0.33
Alcohol consumptiona Nil 93.3 (167/179) 71.4 (40/56) <0.001
  Any 6.7 (12/179) 28.6 (16/56)  
Chronic Liver Disease   2.2 (4/186) 3.9 (3/77) 0.42
  1. P-values from Kruskal-Wallis test (medians), Fisher’s exact test (proportions)
  2. a Most patients drank no alcohol and only 1 patient (male) drank in excess of 21 units/week; given the small number of high alcohol intake, this was analysed as no intake versus any intake of alcohol